Quest Clinical Research

Running trials

• Active, not recruiting

  HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

  NCT07215468· Phase 2· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Source

• Enrolling by invitation

  A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

  NCT05741242· Phase 1/2· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Source

• Active, not recruiting

  Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

  NCT02500849· Phase 1· Source

• Active, not recruiting

  Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients

  NCT02390297· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

  NCT05763576· Phase 1· Source

• Completed

  Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

  NCT05144386· Phase 1· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Source